ad image

Antiviral

1 / 1
Novo Holdings A/S
M&A

Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer

Novo Holdings A/S

PR-M04-22-05Apr 07, 2022
Model Medicines
COVID-19 Antiviral

Model Medicines' Oral Anti-COVID-19 Drug Candidate MDL-001 Found to Significantly Reduce Viral Load in Lungs; Accepted into NIH's Antiviral Program for Pandemics (APP)

Model Medicines

PR-M02-22-05Feb 08, 2022
University of Missouri
COVID-19 Research

MU Study Identifies Mutations Specific to Omicron Variant

University of Missouri

PR-M01-22-17Jan 25, 2022
Drug Approval Trends: Significant Acceleration in Recent Years
Nice Insight Overview

Drug Approval Trends: Significant Acceleration in Recent Years

Nigel Walker

Nice Insight

PAP-Q2-20-NI-001Jul 01, 2020
Q: What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?
COVID-19

Q: What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?

Pharma's Almanac

PAP-Q2-20-RT-001Jul 01, 2020
BioMed X

BioMed X Institute Launches Rapid Antiviral Response Platform to Prevent Future Pandemics

BioMed X

PR-M05-20-NI-037May 26, 2020
Gilead Licenses Antiviral Candidates from Novartis
Licensing

Gilead Licenses Antiviral Candidates from Novartis

Nice Insight

PAO-M08-19-NI-019Aug 15, 2019
Progress on New Antiviral Drugs at Chimerix
Antiviral

Progress on New Antiviral Drugs at Chimerix

Emilie Branch

Pharma's Almanac

PAO-M06-18-NI-019Jun 21, 2018
1 / 1